Compare Modine Manufacturing Company (MOD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs BIO-TECHNE Corp — how do they compare? Modine Manufacturing Company trades at $247.89 (market cap $12.18B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Modine Manufacturing Company and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| MOD | TECH | |
|---|---|---|
Market Cap | $12.18B | $11.16B |
Sector | Technology | Health |
52-Week High | $306.89 | $72.12 |
52-Week Low | $93.71 | $43.31 |
Enterprise Value | $12.54B | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
